MABVAX THERAPEUTICS HOLDINGS, INC. (NASDAQ:MBVX) Files An 8-K Regulation FD Disclosure
ITEM 7.01
|
REGULATION FD DISCLOSURE
|
On June 5, 2017, MabVax Therapeutics Holdings, Inc. (the Company)
issued a press release that reported on results of the Companys
Phase I trial results of antibody therapy MVT-5873 for the
treatment of advanced pancreatic cancer. The press release is
attached hereto as Exhibit 99.1.
issued a press release that reported on results of the Companys
Phase I trial results of antibody therapy MVT-5873 for the
treatment of advanced pancreatic cancer. The press release is
attached hereto as Exhibit 99.1.
The information disclosed under this Item 7.01, including Exhibit
99.1 hereto, is being furnished and shall not be deemed filed for
purposes of Section 18 of the Securities Exchange Act of 1934, as
amended, nor shall it be incorporated by reference into any
registration statement or other document to the Securities Act of
1933, as amended, except as expressly set forth in such filing.
99.1 hereto, is being furnished and shall not be deemed filed for
purposes of Section 18 of the Securities Exchange Act of 1934, as
amended, nor shall it be incorporated by reference into any
registration statement or other document to the Securities Act of
1933, as amended, except as expressly set forth in such filing.
|
ITEM 9.01
|
FINANCIAL STATEMENTS AND EXHIBITS
|
(d)Exhibits.
The exhibit listed in the following Exhibit Index is furnished
with this Current Report on Form 8-K.
with this Current Report on Form 8-K.
|
Exhibit No.
|
Description
|
|
|
99.1
|
Press release issued June 5, 2017
|
